Pathogenesis of the delayed phase of Rauscher virus-induced thrombocytopenia.
BALB/c (H-2d) mice infected with Rauscher murine leukemia virus (RMuLV) developed two phases of thrombocytopenia: an acute phase, probably due to direct virus-platelet interactions, and a delayed phase, starting 2 to 3 wk after virus injection, which was associated with the infection of megakaryocytes by RMuLV and with the expression of RMuLV gp70 and p30 antigens on platelet membranes. This study was concerned with the pathogenesis of this second phase of thrombocytopenia. During this period, the number of marrow megakaryocytes was increased. A peripheral platelet destruction was further indicated by reduced platelet life span. It was shown that radiolabeled platelets, either normal or infected, were submitted to a more rapid clearance in infected recipients than in normal recipients. This might be due to the splenomegaly observed in infected recipients. However, the immediate clearance of gp70+ platelets was more accelerated in infected recipients with high titers of serum anti-gp70 antibodies than in infected recipients without detectable serum anti-gp70 antibodies. In addition, the passive transfer of anti-RMuLV serum to normal BALB/c mice induced a rapid and specific clearance of previously injected radiolabeled platelets expressing RMuLV antigens. In H-2d mice, viral gp70 antigen expression on platelets correlated with the development of delayed thrombocytopenia; but H-2k strains of mice, although susceptible to RMuLV and expressing RMuLV-related antigens on their platelets, did not develop any anti-RMuLV antibodies nor any delayed thrombocytopenia. These results suggest that specific clearance of gp70+ platelets in the presence of significant amounts of serum antiviral antibodies and nonspecific hypersplenism play a role in the development of delayed thrombocytopenia in RMuLV-infected mice.
Grau
G E
GE
Morrow
D
D
Izui
S
S
Lambert
P H
PH
D000818:Animals; D000914:Antibodies, Viral / Q000008:administration & dosage / Q000096:biosynthesis; D000956:Antigens, Viral / Q000276:immunology; D001792:Blood Platelets / Q000276:immunology; D005260:Female; D007106:Immune Sera / Q000008:administration & dosage; D007116:Immunization, Passive; D004915:Leukemia, Erythroblastic, Acute / Q000097:blood / Q000209:etiology* / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D010976:Platelet Count; D011289:Preleukemia / Q000209:etiology / Q000276:immunology; D011925:Rauscher Virus / Q000276:immunology*; D013921:Thrombocytopenia / Q000097:blood / Q000209:etiology* / Q000276:immunology
D000914:Antibodies, Viral; D000956:Antigens, Viral; D007106:Immune Sera